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Bim’s up ﬁrst
Auto-commentary on (Bim is the primary mediator
of Myc-induced apoptosis) in multiple solid tissues.
http://dx.doi.org/10.1016/j.celrep.2014.07.057
Daniel J. Murphy* and Nathiya Muthalagu
Institute of Cancer Sciences; University of Glasgow and the CRUK Beatson Institute for Cancer Research; Glasgow, UK
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In vivo analysis of the genetic determinants of Myc-induced apoptosis reveals a speciﬁc requirement for the Bcl2
family protein Bim (Bcl2l11). Surprisingly, apoptosis induced by Myc in multiple solid tissues does not require p19Arf
(Cdkn2a), whereas Puma (Bbc3) is required only in the context of sensitization by Myc to death induced by DNA
damage.
MYC is one of the most frequently
overexpressed oncogenes across a spec-
trum of human cancers and a growing
body of evidence suggests that MYC may
serve as an obligate conduit of oncogenic
signaling, even in the absence of overt
MYC amplification.1,2 It is textbook
knowledge that the induction of mito-
chondrial apoptosis by MYC serves to
limit the oncogenic potential of this
proto-oncogene, yet the obvious therapeu-
tic potential implied by this remains
largely untapped. This may be in part due
to the widely-held belief that MYC-
induced apoptosis strictly requires an
intact CDKN2AARF/MDM2/TP53 path-
way, which is itself abrogated in the vast
majority of human cancers. In light of
reports from several groups that MYC can
induce apoptosis independently of this
pathway, we sought to re-examine the
genetic requirements for Myc-induced
apoptosis, exploiting the unique features
of the Rosa26-MycERT2 mouse line that
employs a tamoxifen-inducible fusion pro-
tein comprised of human MYC and a
modified ligand-binding domain of the
estrogen receptor to achieve acute deregu-
lation of near-physiological levels of Myc
simultaneously in multiple adult tissues.3
Acute systemic activation of MycERT2 in
this model drives ectopic proliferation in
most adult tissues but apoptosis is
restricted to the intestine, where MycERT2
expression is highest. Activation of
MycERT2 does, however, elicit pro-apo-
ptotic signaling in tissues other than the
intestine, as evidenced by the sensitization
of such tissues to doxorubicin-induced cell
death. We showed that under both cir-
cumstances (apoptosis induced by high
levels of Myc alone and sensitization to an
additional pro-apoptotic signal by lower
levels of Myc) apoptosis occurs unabated
in the absence of p19Arf (encoded by
Cdkn2a) but is suppressed by deletion of
Bcl2l11, which encodes the proapoptotic
protein Bim.4 Our results are closely mir-
rored by those from an independent group
examining MYC-dependent apoptosis in
human tumor cell lines in response to bor-
tezamib,5 effectively ruling out a species-
specific or system-specific requirement for
Bim.
Bim is one of several proapoptotic
Bcl2-Homology domain 3 (BH3)-only
proteins (others include Bbc3/Puma,
Pmaip1/Noxa, p22Bid, and Bad) that
function by binding to antiapoptotic
Bcl2-homologous (BH) proteins, includ-
ing Bcl2 itself, Bcl2l1 (BclXL), Mcl1, and
Bcl2a1a (A1). Sequestration of these antia-
poptotic proteins permits oligomerization
of the effector BH family proteins Bax
and Bak, resulting in pore formation
and thereby permeabilization of the mito-
chondrial outer membrane, effectively
demarcating a point of no return in the
apoptotic cascade. Whether or not a cell
dies in response to proapoptotic signaling
is thus critically dependent upon the rela-
tive levels of pro- and anti-apoptotic BH
family proteins.6 One might then expect
that loss of any one BH3-only protein
would have much the same effect as loss
of any other; however, this is not the case.
We showed that Myc-induced apoptosis
in the intestine requires Bim but not
Puma and, conversely, that apoptosis
induced in the intestine by the DNA-
damaging agent doxorubicin requires
Puma but not Bim; apoptosis induced by
the combination of both requires both
Bim and Puma. Thus, distinct BH3-only
proteins mobilize in response to distinct
death signals, yet can combine to over-
come antiapoptotic buffering.
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A Special Relationship Between
Myc and Bim
Chromatin immunoprecipitation anal-
ysis revealed binding of endogenous Myc
to the Bcl2l11 locus in untransformed
mouse embryo fibroblasts cultured in
10% serum. Importantly, promoter occu-
pancy was not saturated by endogenous
Myc, as activation of MycERT2 resulted in
increased binding. Similar binding kinet-
ics were observed at the BCL2l11 locus in
non-transformed MCF10A human epi-
thelial cells. Strikingly, in these cells no
MYC binding, endogenous or inducible,
was observed at other BH family genes,
including BCL2, BCLX, BBC3 (encoding
PUMA), PMAIP1 (encoding NOXA),
BID, BAD, BAX, or BAK. This contrasts
with promoter occupancy of BH family
genes in tumor cells derived from a geneti-
cally engineered mouse model of pancre-
atic cancer;7 such cells express very high
levels of Myc and exhibit Myc binding to
all of the above promoters except for Noxa
and Bak. Although this difference might
be explained by any number of factors,
from tissue-specific chromatin configura-
tions to differences between species, in
light of recent reports studying promoter
occupancy by different levels of Myc,8,9 a
very simple model emerges. We suggest
that the Bcl2l11 (Bim) promoter contains
high-affinity Myc binding sites that are
bound at lower (i.e., physiological or
somewhat elevated) levels of Myc, whereas
other BH family genes contain lower
affinity binding sites and thus require
higher levels of Myc for binding (Fig. 1).
Induction of Bim by physiological levels
of Myc would not automatically drive
apoptosis because a threshold level of Bim
induction is required to alone overcome
anti-apoptotic buffering.4 Such cells
would nonetheless be “primed” to die in
the presence of another pro-apoptotic sig-
nal or sub-optimal survival signaling. A
striking example of this is the requirement
for Bim during Tgfb1-induced apoptosis
in Apc-deleted intestinal epithelium that
expresses elevated levels of Myc due to
deregulated Ctnnb1 activity.10 This
model has 2 clear implications: (1) higher
levels of Myc elicit a stronger proapoptotic
signal by engaging more BH family genes;
and (2) the requirement for Bim can be
overridden at very high levels of Myc.
Tumor cells evolve continuously to
cope with the challenges of relentless
oncogenic signaling and survival in a hos-
tile milieu. However, their adaptation is
imperfect and rather like a series of stop-
gap measures adopted under extreme
duress. Strategies to exploit this maladap-
tion may lead to improved therapeutic
response rates. Augmenting intrinsic pro-
death signals, for instance through the use
of BH3 mimetics to overcome antiapop-
totic buffering, thus holds great promise
for tumors expressing high levels of MYC.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were
disclosed.
Figure 1. Model for engagement of Bcl2-homologous genes by rising Myc levels. Our data indicate
that, unlike other Bcl2 homologous (BH) family genes, the Bcl2l11 locus (encoding Bim) is bound by
physiological levels of Myc. As Myc levels rise, so does expression of Bim, and a threshold level of
Bim is required to overcome the physiological apoptotic threshold. In cancer, the apoptotic thresh-
old is set much higher, requiring a stronger apoptotic signal to trigger cell death. Oncogenic levels
of Myc may contribute to stronger apoptotic signaling by engaging low stringency elements in the
promoters of multiple BH family genes. The precise sequence in which this might occur remains to
be resolved.
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